Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
05:41pm, Monday, 16'th Feb 2026
LOS ANGELES--(BUSINESS WIRE)---- $RGNX--RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm.
SAN DIEGO--(BUSINESS WIRE)---- $RGNX #biotechnology--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASD
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against REGENXBIO Inc. (RGNX)
10:54am, Monday, 16'th Feb 2026
NEW YORK, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland o
NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of REGENXBIO In
Regenxbio: Cautiously Bullish After FDA Setbacks
06:07am, Friday, 13'th Feb 2026
REGENXBIO's NAV AAV platform has given them a diversified pipeline. They have RGX-314 and RGX-202 as primary value drivers with promising 2026 catalysts. RGX-314 is being developed in partnership with
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
06:51pm, Thursday, 12'th Feb 2026
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are advised to co
FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment
08:51am, Tuesday, 10'th Feb 2026
In May 2025, the FDA accepted the RGX-121 BLA under the accelerated approval pathway; however, the Prescription Drug User Fee Act (PDUFA) goal date was extended from November 9, 2025, to February 8, 2
First Look: Novo sues Hims, BP halts buybacks, Meta faces trial
07:39am, Tuesday, 10'th Feb 2026
Stock News Novo sues Hims over compounded weight-loss drugs: Novo Nordisk (NVO) filed suit to stop Hims and Hers Health (HIMS) from selling compounded semaglutide
US FDA declines to approve Regenxbio's rare disease drug
04:13pm, Monday, 09'th Feb 2026
Regenxbio said on Monday the U.S. Food and Drug Administration has declined to approve its drug for a rare disease.
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
04:05pm, Monday, 09'th Feb 2026
FDA issues Complete Response Letter for RGX-121 (clemidsogene lanparvovec) for treatment of Mucopolysaccharidosis II (MPS II) REGENXBIO plans to work with FDA on a path forward with the goal of resubm
Ongoing Investigation: REGENXBIO Inc. (RGNX) May Have Misled Shareholders - Levi & Korsinsky Investigates
12:21am, Monday, 09'th Feb 2026
New York, New York--(Newsfile Corp. - February 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning po
RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm
03:06pm, Tuesday, 03'rd Feb 2026
LOS ANGELES--(BUSINESS WIRE)---- $RGNX--RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
01:57pm, Tuesday, 03'rd Feb 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. (“Regenxbio” or the “Company”) (NASDAQ: RGNX). Such investors are
Lost Money on REGENXBIO Inc. (RGNX)? Possible Fraud - Contact Levi & Korsinsky Today
12:18am, Monday, 02'nd Feb 2026
New York, New York--(Newsfile Corp. - February 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning po
